N2off Inc. Enters Fourth Loan Agreement to Support MitoCareX Acquisition Process

Reuters

Aug 19

N2off Inc. Enters Fourth Loan Agreement to Support MitoCareX Acquisition Process

N2off Inc. has announced an update regarding its acquisition of MitoCareX Bio Ltd., a private Israeli company. As per the announcement, N2off Inc. has entered into a Fourth Loan Agreement with MitoCareX and L.I.A. Pure Capital Ltd., agreeing to loan $372,000 to MitoCareX. The loan will assist MitoCareX in financing its ongoing costs until the acquisition is finalized. The loan features an interest rate tied to the USD exchange rate fluctuation plus 3%, with a term of six months. In the event that MitoCareX becomes a subsidiary of N2off Inc., any outstanding loan amount will be deducted from future financial allocations to MitoCareX within the first year of the acquisition. Pure Capital has guaranteed the loan's repayment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. N2off Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-012130), on August 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2560138073"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560138073\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560138073?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-19 04:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560138073","market":"fut","top_or_hot":-1,"title":"N2off Inc. Enters Fourth Loan Agreement to Support MitoCareX Acquisition Process","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      N2off Inc. Enters Fourth Loan Agreement to Support MitoCareX Acquisition Process\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        N2off Inc. has announced an update regarding its acquisition of MitoCareX Bio Ltd., a private Israeli company. As per the announcement, N2off Inc. has entered into a Fourth Loan Agreement with MitoCareX and L.I.A. Pure Capital Ltd., agreeing to loan $372,000 to MitoCareX. The loan will assist MitoCareX in financing its ongoing costs until the acquisition is finalized. The loan features an interest rate tied to the USD exchange rate fluctuation plus 3%, with a term of six months. In the event that MitoCareX becomes a subsidiary of N2off Inc., any outstanding loan amount will be deducted from future financial allocations to MitoCareX within the first year of the acquisition. Pure Capital has guaranteed the loan's repayment.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. N2off Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-012130), on August 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>N2off Inc. Enters Fourth Loan Agreement to Support MitoCareX Acquisition Process</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nN2off Inc. Enters Fourth Loan Agreement to Support MitoCareX Acquisition Process\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-19 04:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      N2off Inc. Enters Fourth Loan Agreement to Support MitoCareX Acquisition Process\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        N2off Inc. has announced an update regarding its acquisition of MitoCareX Bio Ltd., a private Israeli company. As per the announcement, N2off Inc. has entered into a Fourth Loan Agreement with MitoCareX and L.I.A. Pure Capital Ltd., agreeing to loan $372,000 to MitoCareX. The loan will assist MitoCareX in financing its ongoing costs until the acquisition is finalized. The loan features an interest rate tied to the USD exchange rate fluctuation plus 3%, with a term of six months. In the event that MitoCareX becomes a subsidiary of N2off Inc., any outstanding loan amount will be deducted from future financial allocations to MitoCareX within the first year of the acquisition. Pure Capital has guaranteed the loan's repayment.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. N2off Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-012130), on August 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL4SsGNf:1","article_id":"2560138073","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560138073","pubTimestamp":1755547590,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"N2off Inc. has announced an update regarding its acquisition of MitoCareX Bio Ltd., a private Israeli company. As per the announcement, N2off Inc. has entered into a Fourth Loan Agreement with MitoCareX and L.I.A. Pure Capital Ltd., agreeing to loan $372,000 to MitoCareX. The loan will assist MitoCareX in financing its ongoing costs until the acquisition is finalized. The loan features an interest rate tied to the USD exchange rate fluctuation plus 3%, with a term of six months. In the event that MitoCareX becomes a subsidiary of N2off Inc., any outstanding loan amount will be deducted from future financial allocations to MitoCareX within the first year of the acquisition. Pure Capital has guaranteed the loan's repayment.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","NITO":"N2OFF, Inc","BK4093":"化肥与农用药剂"},"translate_title":"N2off Inc.签订第四份贷款协议以支持MitoCareX收购流程","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NITO":0.9},"content_text":"N2off Inc. Enters Fourth Loan Agreement to Support MitoCareX Acquisition Process\n    \n\n        N2off Inc. has announced an update regarding its acquisition of MitoCareX Bio Ltd., a private Israeli company. As per the announcement, N2off Inc. has entered into a Fourth Loan Agreement with MitoCareX and L.I.A. Pure Capital Ltd., agreeing to loan $372,000 to MitoCareX. The loan will assist MitoCareX in financing its ongoing costs until the acquisition is finalized. The loan features an interest rate tied to the USD exchange rate fluctuation plus 3%, with a term of six months. In the event that MitoCareX becomes a subsidiary of N2off Inc., any outstanding loan amount will be deducted from future financial allocations to MitoCareX within the first year of the acquisition. Pure Capital has guaranteed the loan's repayment.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. N2off Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-012130), on August 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}